Society and culture Bicalutamide

1 society , culture

1.1 names
1.2 cost , generics
1.3 sales , usage
1.4 regulation

society , culture
names

bicalutamide generic name of drug in english , french , inn, usan, usp, ban, dcf, aan, , jan. referred bicalutamidum in latin, bicalutamida in spanish , portuguese, bicalutamid in german, , bikalutamid in russian , other slavic languages. -lutamide suffix corresponds nsaas. bicalutamide known former developmental code name ici-176,334.

bicalutamide marketed astrazeneca in oral tablet form under brand names casodex, cosudex, calutide, calumid, , kalumid in many countries. marketed under brand names bicadex, bical, bicalox, bicamide, bicatlon, bicusan, binabic, bypro, calutol, , ormandyl among others in various countries. drug sold under large number of generic trade names such apo-bicalutamide, bicalutamide accord, bicalutamide actavis, bicalutamide bluefish, bicalutamide kabi, bicalutamide sandoz, , bicalutamide teva well. combination formulation of bicalutamide , goserelin marketed astrazeneca in australia , new zealand under brand name zolacos-cp.

cost , generics

bicalutamide off-patent , available generic, , cost low in comparison number of other similar medications (from us$10 us$15.44 30-day supply of once-daily 50 mg tablets). brand name casodex costs us$556.17 30-day supply of once-daily 50 mg tablets of 2017. unlike bicalutamide, newer nsaa enzalutamide still on-patent, , reason, far more expensive in comparison (us$7,450 30-day supply of 2015).

the patent protection of 3 of first-generation nsaas has expired , flutamide , bicalutamide both available relatively inexpensive generics. nilutamide, on other hand, has been poor third competitor flutamide , bicalutamide and, in relation fact, has not been developed generic , available brand name nilandron, @ least in u.s.

bicalutamide far less expensive gnrh analogues, which, in spite of having been off-patent many years, have been reported (in 2013) typically cost us$10,000–$15,000 per year (or us$1,000 per month) of treatment.

sales , usage

sales of bicalutamide (as casodex) worldwide peaked @ us$1.3 billion in 2007, , has been described billion-dollar-a-year drug prior losing patent protection starting in 2007. in 2014, despite introduction of abiraterone acetate in 2011 , enzalutamide in 2012, bicalutamide still commonly prescribed drug in treatment of metastatic castration-resistant prostate cancer (mcrpc). moreover, in spite of being off-patent, bicalutamide said still generate few hundred million dollars in sales per year astrazeneca. total worldwide sales of brand name casodex approximately us$13.0 billion of end of 2016.

between january 2007 , december 2009 (a period of 3 years), 1,232,143 prescriptions of bicalutamide dispensed in u.s., or 400,000 prescriptions per year. during time, bicalutamide accounted 87.2% of nsaa market, while flutamide accounted 10.5% of , nilutamide 2.3% of it. approximately 96% of bicalutamide prescriptions written diagnosis codes indicated neoplasm. 1,200, or 0.1% of bicalutamide prescriptions dispensed pediatric patients (age 0–16).

regulation

bicalutamide prescription drug. not controlled substance in country , therefore not illegal drug. however, manufacture, sale, distribution, , possession of prescription drugs still subject legal regulation throughout world.